Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals Limited has announced a change in the director’s interest in securities, specifically involving Vincent Ippolito. An off-market transfer of 8,000,000 fully paid ordinary shares was made from a direct to an indirect holding under the Ippolito Trust. This change reflects a strategic adjustment in the director’s holdings but does not indicate any immediate impact on the company’s operations or market positioning.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of dermatology and antimicrobial products. The company is engaged in creating innovative solutions for skin diseases and infections, aiming to address unmet medical needs in these areas.
Average Trading Volume: 11,843,217
Technical Sentiment Signal: Sell
Current Market Cap: A$323.6M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.